In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
An ongoing Candida auris outbreak in the New York metropolitan area is the largest recorded to date in North America. Laboratory surveillance revealed NY C. auris isolates are resistant to fluconazole, with variable resistance to other currently used broad-spectrum antifungal drugs, and that several isolates are panresistant. Thus, there is an urgent need for new drugs with a novel mechanism of action to combat the resistance challenge. Manogepix (MGX) is a first-in-class agent that targets the fungal Gwt1 enzyme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This is consistent with previous in vitro studies showing MGX to be the most potent antifungal tested against C. auris isolates (21, 22).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [21]
In the citing paper
“Another study that focused on 200 C. auris strains collected between 2017 and 2020 in New York and New Jersey reported low MICs for MGX even against pan-resistant strains shown to be resistant to the 3 main classes of antifungal drugs (i.e., azoles, polyenes, and echinocandins) (21).”
From Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 Trial (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 3×
“variable patterns of resistance to amphotericin B, azoles, and echinocandins; (3) MGX”
BackgroundResultKathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532 · cited 1×
“The observed pattern is higher than that reported in other published studies, including South Asian clade I isolates (3, 29, 36), and also included organisms with AMB MIC values as high as 32 mg/liter.”
ResultChow, N. A., Muñoz, J. F., Gade, L., Berkow, E., Li, X., Welsh, R. M., Forsberg, K., Lockhart, S. R., Adam, R., Alanio, A., et al. (2020) · doi:10.1101/2020.01.06.896548 · Cited by 463
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03880.x · Cited by 451
Turnidge, J., Kahlmeter, G., & Kronvall, G. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01377.x · Cited by 397 · cited 2×
“The WT-UL for MGX for MGX were estimated using the Microsoft Excel spreadsheet calculator ECOFFinder (27, 28).”
MethodInfluentialPotential Fifth Clade of Candida auris, Iran, 2018
Chow, N. A., de Groot, T., Badali, H., Abastabar, M., Chiller, T. M., & Meis, J. F. (2019) · Emerging Infectious Diseases · doi:10.3201/eid2509.190686 · Cited by 356 · cited 1×
“auris emerged independently in four regions, namely, South Asia, East Asia, Africa, and South America, defined by clades I, II, II, and IV, respectively (3), with Iranian clade V arising more recently (4).”
BackgroundVallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6544e1 · Cited by 302
Self-citationCandida auris in Healthcare Facilities, New York, USA, 2013–2017
Adams, E., Quinn, M., Tsay, S., Poirot, E., Chaturvedi, S., Southwick, K., Greenko, J., Fernandez, R., Kallen, A., Vallabhaneni, S., et al. (2018) · Emerging Infectious Diseases · doi:10.3201/eid2410.180649 · Cited by 284
Self-citationArendrup, M. C., Prakash, A., Meletiadis, J., Sharma, C., & Chowdhary, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00485-17 · Cited by 270
Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14121 · Cited by 247 · cited 2×
“isolates tested to date; (2) MGX MICs were unchanged against C.”
BackgroundSelf-citationUnderstanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Kordalewska, M., Lee, A., Park, S., Berrio, I., Chowdhary, A., Zhao, Y., & Perlin, D. S. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00238-18 · Cited by 247 · cited 1×
“auris in New York that is exacerbated by the limited availability of effective treatment options (1, 8).”
BackgroundCandida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
Ostrowsky, B., Greenko, J., Adams, E., Quinn, M., O’Brien, B., Chaturvedi, V., Berkow, E., Vallabhaneni, S., Forsberg, K., Chaturvedi, S., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6901a2 · Cited by 246
Self-citationIn Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200 · cited 1×
“krusei, and a wide variety of pathogenic molds (20, 21).”
BackgroundHope on the Horizon: Novel Fungal Treatments in Development
Rauseo, A. M., Coler-Reilly, A., Larson, L., & Spec, A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa016 · Cited by 199 · cited 1×
“The fosmanogepix efficacy observed in animal models awaits further confirmation from ongoing trials for invasive candidiasis/candidemia (37).”
BackgroundWatanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K., & Hata, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00731-11 · Cited by 169 · cited 2×
“Inhibition of Gwt1 prevents the appropriate localization of cell wall mannoproteins, which compromises cell wall integrity, biofilm formation, and germ tube formation and results in severe fungal growth defects (12, 13).”
BackgroundZhu, Y., O’Brien, B., Leach, L., Clarke, A., Bates, M., Adams, E., Ostrowsky, B., Quinn, M., Dufort, E., Southwick, K., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01503-19 · Cited by 162 · cited 6×
“0 mg/liter), with emerging resistance to 1 or more echinocandins (6).”
BackgroundInfluentialSelf-citationIn Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Hager, C. L., Larkin, E. L., Long, L., Zohra Abidi, F., Shaw, K. J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02319-17 · Cited by 139 · cited 10×
“The susceptibility breakpoints of the Centers for Disease Control and Prevention were used to assess antifungal resistance patterns in C. auris (FLC, 32; AMB, 2; AFG, 4; CAS, 2; and MFG, 4 mg/liter), and the Etest AMB MIC value of 1.5 mg/liter was rounded up to 2.0 mg/liter as described (https://www.cdc.gov/fungal/can…”
BackgroundInfluentialSelf-citationGWT1 Gene Is Required for Inositol Acylation of Glycosylphosphatidylinositol Anchors in Yeast
Umemura, M., Okamoto, M., Nakayama, K.-I., Sagane, K., Tsukahara, K., Hata, K., & Jigami, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301044200 · Cited by 127
Espinel‐Ingroff, A., & Turnidge, J. D. (2016) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.04.001 · Cited by 123 · cited 2×
“The WT-UL for MGX for MGX were estimated using the Microsoft Excel spreadsheet calculator ECOFFinder (27, 28).”
MethodInfluentialIn Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
Self-citationTsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe, N., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., et al. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03481.x · Cited by 118
McLellan, C. A., Whitesell, L., King, O. D., Lancaster, A. K., Mazitschek, R., & Lindquist, S. (2012) · ACS Chemical Biology · doi:10.1021/cb300235m · Cited by 115 · cited 1×
“Inhibition of Gwt1 prevents the appropriate localization of cell wall mannoproteins, which compromises cell wall integrity, biofilm formation, and germ tube formation and results in severe fungal growth defects (12, 13).”
BackgroundPfaller, M. A., Huband, M. D., Flamm, R. K., Bien, P. A., & Castanheira, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00840-19 · Cited by 80
Wiederhold, N. P., Najvar, L. K., Shaw, K. J., Jaramillo, R., Patterson, H., Olivo, M., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01120-19 · Cited by 71 · cited 1×
“Similarly, in a delayed treatment model utilizing a FLC-resistant strain, fosmanogepix-treated mice demonstrated significant improvements in survival at day 21 as well as reductions in kidney burden (19).”
BackgroundSelf-citationZhao, M., Lepak, A. J., VanScoy, B., Bader, J. C., Marchillo, K., Vanhecker, J., Ambrose, P. G., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02542-17 · Cited by 68
O’Brien, B., Chaturvedi, S., & Chaturvedi, V. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02195-19 · Cited by 63
Self-citationPfaller, M. A., Hata, K., Jones, R. N., Messer, S. A., Moet, G. J., & Castanheira, M. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.05.001 · Cited by 60 · cited 1×
“krusei, and a wide variety of pathogenic molds (20, 21).”
BackgroundViriyakosol, S., Kapoor, M., Okamoto, S., Covel, J., Soltow, Q. A., Trzoss, M., Shaw, K. J., & Fierer, J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01715-18 · Cited by 59
Self-citationEvaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
Kapoor, M., Moloney, M., Soltow, Q. A., Pillar, C. M., & Shaw, K. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01387-19 · Cited by 59 · cited 1×
“The promising profile of MGX includes a unique mode of action and low potential for the development of spontaneous resistance for several Candida species (38).”
BackgroundSelf-citationActivity of novel antifungal compound APX001A against a large collection of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky302 · Cited by 57 · cited 1×
“06 mg/liter was within two dilutions of the ranges reported earlier (16, 17).”
MethodArendrup, M. C., Chowdhary, A., Astvad, K. M. T., & Jørgensen, K. M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01225-18 · Cited by 53 · cited 5×
“(18) reported a wider range of MGX (EUCAST) MIC values (range, 0.”
BackgroundMethodInfluentialBranco, J., Silva, A. P., Silva, R. M., Silva-Dias, A., Pina-Vaz, C., Butler, G., Rodrigues, A. G., & Miranda, I. M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00842-15 · Cited by 49
Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. P., Van Hoogdalem, E.-J., Kramer, W., & Wedel, P. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1390 · Cited by 45
Self-citationAPX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
Gebremariam, T., Alkhazraji, S., Alqarihi, A., Jeon, H. H., Gu, Y., Kapoor, M., Shaw, K. J., & Ibrahim, A. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01713-18 · Cited by 43
Self-citationJørgensen, K. M., Astvad, K. M. T., Hare, R. K., & Arendrup, M. C. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00073-19 · Cited by 42
Hodges, M. R., Ople, E., Shaw, K. J., Mansbach, R., Van Marle, S. J., Van Hoogdalem, E.-J., Wedel, P., & Kramer, W. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx163.1370 · Cited by 40
Self-citationEnhanced Efflux Pump Expression in Candida Mutants Results in Decreased Manogepix Susceptibility
Liston, S. D., Whitesell, L., Kapoor, M., Shaw, K. J., & Cowen, L. E. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00261-20 · Cited by 39
Self-citationArendrup, M. C., & Jørgensen, K. M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00429-20 · Cited by 37 · cited 1×
“auris as well as other pathogenic yeasts (18, 40).”
BackgroundYou, L., Qian, W., Yang, Q., Mao, L., Zhu, L., Huang, X., Jin, J., & Meng, H. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02496-16 · Cited by 31
2039. New York State 2016–2018: Progression from Candida auris Colonization to Bloodstream Infection
Southwick, K., Adams, E. H., Greenko, J., Ostrowsky, B., Fernandez, R., Patel, R., Quinn, M., Vallabhaneni, S., Denis, R. J., Erazo, R., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy210.1695 · Cited by 26
Self-citationRicardo, E., Grenouillet, F., Miranda, I. M., Silva, R. M., Eglin, G., Devillard, N., Rodrigues, A. G., & Pina‐Vaz, C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01651-19 · Cited by 12
Research works printed but not linked: 2
- Hata K, Horii T, Miyazaki M, Watanabe N. 2011. In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, abstr F1-1377. Abstr Interscience Conference on Antimicrobial Agents Chemotherapy. American Society for Microbiology, Washington, DC.
- CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3. Vol. 28. No. 14. Clinical Laboratory Standards Institute, Wayne, PA.
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
Shaw, K. J., & Ibrahim, A. S. (2020) · Journal of Fungi · doi:10.3390/jof6040239 · Cited by 229
“MGX was 8- to 32-fold more active than the echinocandins, 16- to 64-fold more active than the azoles, and 64-fold more active than AMB [35].”
BackgroundInfluentialSelf-citationHoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 185
Antifungal Resistance and the Role of New Therapeutic Agents
Logan, A., Wolfe, A. L., & Williamson, J. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00782-5 · Cited by 117
New treatment options for critically important WHO fungal priority pathogens
Kriegl, L., Egger, M., Boyer, J., Hoenigl, M., & Krause, R. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.03.006 · Cited by 105
Metadata
- Authors
- Zhu, Y., Kilburn, S., Kapoor, M., Chaturvedi, S., Shaw, K. J., & Chaturvedi, V.
- Affiliations
- New York State Department of Health (US)
- Amplyx Pharmaceuticals (United States) (US)
- Hearts Consulting Group, Poway, California, USA
- Corresponding author
- Shaw, Karen Joy
- Chaturvedi, Vishnu
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2020-10-20
- Volume
- 64
- Issue
- 11
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC7577132
- OpenAlex
- W3080618403
- Cited by
- 50
- References
- 41
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 9 · 2023: 10 · 2022: 8 · 2021: 8 · 2020: 1
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amplyx Pharmaceuticals
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- manogepix, Candida auris, multidrug resistance, panresistance, fluconazole resistance, antifungal resistance, in vitro antifungal activity
- MeSH terms
- Aminopyridines, Antifungal Agents, Candida, Disease Outbreaks, Isoxazoles, Microbial Sensitivity Tests, New York, North America
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.